vs

Side-by-side financial comparison of Pulmonx Corp (LUNG) and Pioneer Bancorp, Inc. (PBFS). Click either name above to swap in a different company.

Pioneer Bancorp, Inc. is the larger business by last-quarter revenue ($25.0M vs $20.6M, roughly 1.2× Pulmonx Corp). Pioneer Bancorp, Inc. runs the higher net margin — 82.1% vs -66.3%, a 148.4% gap on every dollar of revenue. Over the past eight quarters, Pioneer Bancorp, Inc.'s revenue compounded faster (144.9% CAGR vs -0.5%).

Pulmonx Corp is a global medical tech firm focused on interventional pulmonology solutions. It develops minimally invasive endobronchial valves to treat severe COPD and emphysema, with products sold across North America, Europe, and Asia-Pacific for patients with advanced lung conditions.

Pioneer Bancorp, Inc. (MD) is a bank holding company operating as the parent entity of Pioneer Bank. It provides a full suite of retail and commercial banking products and services, including deposit accounts, residential and commercial mortgages, consumer loans, and small business financing, primarily serving individual and corporate customers across local communities in Maryland, U.S.

LUNG vs PBFS — Head-to-Head

Bigger by revenue
PBFS
PBFS
1.2× larger
PBFS
$25.0M
$20.6M
LUNG
Higher net margin
PBFS
PBFS
148.4% more per $
PBFS
82.1%
-66.3%
LUNG
Faster 2-yr revenue CAGR
PBFS
PBFS
Annualised
PBFS
144.9%
-0.5%
LUNG

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
LUNG
LUNG
PBFS
PBFS
Revenue
$20.6M
$25.0M
Net Profit
$-13.7M
$3.7M
Gross Margin
77.9%
Operating Margin
-40.9%
21.3%
Net Margin
-66.3%
82.1%
Revenue YoY
-8.7%
Net Profit YoY
5.5%
EPS (diluted)
$-0.33
$0.16

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LUNG
LUNG
PBFS
PBFS
Q1 26
$20.6M
Q4 25
$22.6M
$25.0M
Q3 25
$21.5M
$24.0M
Q2 25
$23.9M
$24.4M
Q1 25
$22.5M
$22.8M
Q4 24
$23.8M
Q3 24
$20.4M
$22.0M
Q2 24
$20.8M
$20.9M
Net Profit
LUNG
LUNG
PBFS
PBFS
Q1 26
$-13.7M
Q4 25
$-10.4M
$3.7M
Q3 25
$-14.0M
$4.3M
Q2 25
$-15.2M
$6.5M
Q1 25
$-14.4M
$5.8M
Q4 24
$-13.2M
Q3 24
$-14.1M
$6.3M
Q2 24
$-15.3M
$3.9M
Gross Margin
LUNG
LUNG
PBFS
PBFS
Q1 26
77.9%
Q4 25
77.6%
Q3 25
74.7%
Q2 25
72.1%
Q1 25
72.5%
Q4 24
74.0%
Q3 24
73.7%
Q2 24
73.7%
Operating Margin
LUNG
LUNG
PBFS
PBFS
Q1 26
-40.9%
Q4 25
-43.8%
21.3%
Q3 25
-66.9%
23.4%
Q2 25
-62.0%
33.3%
Q1 25
-64.6%
32.5%
Q4 24
-56.5%
Q3 24
-69.3%
37.2%
Q2 24
-75.2%
24.1%
Net Margin
LUNG
LUNG
PBFS
PBFS
Q1 26
-66.3%
Q4 25
-46.1%
82.1%
Q3 25
-64.9%
18.0%
Q2 25
-63.6%
26.4%
Q1 25
-64.1%
25.3%
Q4 24
-55.4%
Q3 24
-69.4%
28.7%
Q2 24
-73.7%
107.4%
EPS (diluted)
LUNG
LUNG
PBFS
PBFS
Q1 26
$-0.33
Q4 25
$-0.25
$0.16
Q3 25
$-0.34
$0.18
Q2 25
$-0.38
$0.26
Q1 25
$-0.36
$0.23
Q4 24
$-0.33
Q3 24
$-0.36
$0.25
Q2 24
$-0.39
$0.15

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LUNG
LUNG
PBFS
PBFS
Cash + ST InvestmentsLiquidity on hand
$61.6M
Total DebtLower is stronger
$37.3M
Stockholders' EquityBook value
$45.8M
$323.9M
Total Assets
$120.0M
$2.2B
Debt / EquityLower = less leverage
0.82×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LUNG
LUNG
PBFS
PBFS
Q1 26
$61.6M
Q4 25
$69.8M
Q3 25
$76.5M
Q2 25
$75.5M
Q1 25
$74.6M
Q4 24
$70.9M
Q3 24
$63.3M
Q2 24
$63.5M
Total Debt
LUNG
LUNG
PBFS
PBFS
Q1 26
$37.3M
Q4 25
$37.1M
Q3 25
$37.1M
Q2 25
$37.1M
Q1 25
$37.2M
Q4 24
$37.2M
Q3 24
$37.2M
Q2 24
$37.2M
Stockholders' Equity
LUNG
LUNG
PBFS
PBFS
Q1 26
$45.8M
Q4 25
$54.1M
$323.9M
Q3 25
$60.0M
$314.2M
Q2 25
$69.1M
$314.2M
Q1 25
$77.7M
$310.7M
Q4 24
$85.8M
Q3 24
$93.9M
$303.8M
Q2 24
$101.2M
$296.5M
Total Assets
LUNG
LUNG
PBFS
PBFS
Q1 26
$120.0M
Q4 25
$129.3M
$2.2B
Q3 25
$138.3M
$2.2B
Q2 25
$147.2M
$2.1B
Q1 25
$150.7M
$2.1B
Q4 24
$162.8M
Q3 24
$167.4M
$2.0B
Q2 24
$172.6M
Debt / Equity
LUNG
LUNG
PBFS
PBFS
Q1 26
0.82×
Q4 25
0.69×
Q3 25
0.62×
Q2 25
0.54×
Q1 25
0.48×
Q4 24
0.43×
Q3 24
0.40×
Q2 24
0.37×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LUNG
LUNG
PBFS
PBFS
Operating Cash FlowLast quarter
$11.1M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
2.97×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LUNG
LUNG
PBFS
PBFS
Q1 26
Q4 25
$-7.1M
$11.1M
Q3 25
$-8.2M
$3.9M
Q2 25
$-3.9M
$5.1M
Q1 25
$-13.2M
$-3.5M
Q4 24
$-6.7M
Q3 24
$-7.2M
$1.9M
Q2 24
$-5.8M
$9.0M
Free Cash Flow
LUNG
LUNG
PBFS
PBFS
Q1 26
Q4 25
$-7.1M
Q3 25
$-8.3M
Q2 25
$-4.0M
Q1 25
$-13.5M
Q4 24
$-6.8M
Q3 24
$-7.7M
Q2 24
$-6.2M
FCF Margin
LUNG
LUNG
PBFS
PBFS
Q1 26
Q4 25
-31.4%
Q3 25
-38.4%
Q2 25
-16.6%
Q1 25
-60.0%
Q4 24
-28.8%
Q3 24
-37.6%
Q2 24
-30.0%
Capex Intensity
LUNG
LUNG
PBFS
PBFS
Q1 26
Q4 25
0.1%
Q3 25
0.4%
Q2 25
0.2%
Q1 25
1.3%
Q4 24
0.5%
Q3 24
2.0%
Q2 24
2.3%
Cash Conversion
LUNG
LUNG
PBFS
PBFS
Q1 26
Q4 25
2.97×
Q3 25
0.90×
Q2 25
0.78×
Q1 25
-0.61×
Q4 24
Q3 24
0.30×
Q2 24
2.30×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons